Stockscreener 앱 받기
134.36
2.96%
3.86
Gilead Sciences Inc 주식(GILD)의 최신 뉴스
LSV Asset Management Has $508.91 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Global Retirement Partners LLC Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
Is It Time To Reassess Gilead Sciences (GILD) After Strong Multi Year Share Price Gains - Yahoo Finance
Gilead Sciences Inc. (NASDAQ: GILD) Holds Steady as HIV and Oncology Portfolio Drives Income - foreignpolicyjournal.com
Gilead Sciences Inc Stock (GILD) Closed Up by 3.04% on May 22: Drivers Behind the Movement - TradingKey
Gilead wins FDA approval for first hepatitis delta treatment By Investing.com - Investing.com Nigeria
Gilead's drug wins first-ever US approval for deadly liver infection - Reuters
GILD Stock Jumps After Winning Accelerated FDA Approval For HDV Treatment - Yahoo Finance
US FDA approves Gilead's drug for deadly liver infection - Yahoo
Gilead Sciences stock rises after FDA approves HDV treatment - Investing.com
New Gilead shot is first FDA-approved treatment for deadly hepatitis D - Stock Titan
Gilead Sciences stock rises after FDA approves HDV treatment By Investing.com - Investing.com Canada
(bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV) - Business Wire
GILD: Gilead's Trodelvy Gains Positive Opinion for TNBC Treatmen - GuruFocus
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $180 - Moomoo
GILD Receives Positive EMA Opinion for Trodelvy in Breast Cancer Treatment - GuruFocus
Gilead’s Trodelvy receives EU committee backing for breast cancer By Investing.com - Investing.com Australia
Gilead inks $140M API supply deal, tightening ties to Korean manufacturer - BioSpace
in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors - Business Wire
Keudell Morrison Wealth Management Purchases Shares of 16,022 Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences acquires Tubulis for $5bn - Yahoo Finance
Gilead Sciences completes Tubulis acquisition for $5bn - Pharmaceutical Technology
Zacks Research Forecasts Weaker Earnings for Gilead Sciences - MarketBeat
PNC Financial Services Group Inc. Has $58.19 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Northwestern Mutual Wealth Management Co. Buys 13,252 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Key facts: Gilead buys Tubulis for $3.15B; remdesivir vs Bundibugyo - TradingView
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology - BioSpace
Fidelity Low-Priced Stock K6 Fund's Gilead Sciences Inc(GILD) Holding History - GuruFocus
ETFs Investing in Gilead Sciences, Inc. Stocks - TradingView
Gilead Sciences, Inc. completed the acquisition of Tubulis GmbH from a group of shareholders. - marketscreener.com
Gilead Sciences, Inc. Cash Flow – BVL:GILDUS - TradingView
Gilead Sciences, Inc. Revenue Breakdown – BVL:GILDUS - TradingView
Gilead Sciences (GILD) Is Among The Best Extremely Profitable Stocks To Buy According To Wall Street Analysts - Yahoo Finance
Gilead pledges 400K AmBisome doses to fight visceral leishmaniasis in expanded WHO collab - Fierce Pharma
Gilead Sciences Completes Acquisition of Tubulis - Contract Pharma
Why Gilead Sciences Is Now A Hold (Rating Upgrade) (NASDAQ:GILD) - Seeking Alpha
Gilead completes $3.15 billion acquisition of Tubulis By Investing.com - Investing.com Canada
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio - Business Wire
Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now - Yahoo Finance
Gilead Renews WHO Partnership to Fight Deadly Kala-Azar - Contract Pharma
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease - BioSpace
Leonteq Securities AG Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences extends WHO partnership to fight visceral leishmaniasis - StreetInsider
400,000 drug vials to fight a fatal parasite in 74% of VL hotspots - Stock Titan
FDA Approval for BIKTARVY issued to GILEAD SCIENCES INC - Quantisnow
Maxim Group upgrades Gilead Sciences (GILD) - MSN
Gilead Sciences (GILD) Announces Issuance of Senior Notes in New Indenture Agreement - GuruFocus
Gilead Sciences Launches New $3 Billion Senior Notes - TipRanks
Gilead Sciences issues $3 billion in senior notes across four tranches - StreetInsider
Gilead Sciences (GILD) prices multiple senior note series due 2028–2034 - Stock Titan
Gilead Sciences Raised to Buy From Hold by Maxim Group - Moomoo
GILD Maintains a $122 Price Target Following Healthcare Conferen - GuruFocus
Gilead Sciences (NASDAQ:GILD) Upgraded to Buy at Maxim Group - MarketBeat
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Maxim Upgrades Gilead Sciences to Buy From Hold, Price Target Is $165 - Moomoo
Maxim Group Upgrades Gilead Sciences(GILD.US) to Buy Rating, Announces Target Price $165 - Moomoo
Morgan Stanley Reassesses Gilead Sciences (GILD) Outlook Following Quarterly Report - Yahoo Finance
Jag Capital Management LLC Buys New Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Mitsubishi UFJ Asset Management UK Ltd. - MarketBeat
Fideuram Intesa Sanpaolo Private Banking S.P.A. Takes $50.80 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Banque Cantonale Vaudoise - MarketBeat
Atle Fund Management AB Sells 27,373 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Earnings call transcript: Gilead Sciences beats Q1 2026 forecasts, stock dips - Investing.com Nigeria
Yuhan expands API deals with Gilead, boosts South Korea productionCHOSUNBIZ - Chosunbiz
Yuhan Signs 210.2 Billion Won API Supply Deal with Gilead - Seoul Economic Daily
0.56%
0.19%
자본화:
|
볼륨(24시간):